Posted 02 November 2020 | By Denise Fulton Lessons learned from early COVID-19 emergency use authorizations (EUAs) granted by the US Food and Drug Administration (FDA) could go far to improve public trust in a future EUA or approval of a vaccine – and in the regulatory process itself, Herschel Nachlis writes in the Health Affairs Blog.